Dose-Dependent Pharmacokinetics of Glycyrrhizin in Rats

Shiro ISHIDA,* Yoko SAKIYA, Tsuomu ICHIKAWA, and Zenei Taira

Faculty of Pharmaceutical Sciences, Tokushima Bunri University, Yamanashiro-cho, Tokushima-shi 770, Japan. Received January 25, 1992

The dose-dependent pharmacokinetics of glycyrrhizin (GLZ) was investigated by measuring drug disappearance from plasma and biliary excretion in rats. The decline in plasma concentration was biexponential after an i.v. dose of 5, 10, 20, or 50 mg/kg. Dosage, however, had a marked effect on the pharmacokinetics, with a greater-than-proportional increase in area under the plasma concentration curve (AUC) at doses of 20 and 50 mg/kg, even though the increase was proportional at doses of 5 and 10 mg/kg. There was also a significant increase of the steady-state distribution volume (Vdss), as well as significant decreases in total body (CLint) and biliary (CLb) clearances, at 20 and 50 mg/kg from those at 5—10 and 5—20 mg/kg, respectively. The AUC, Vdss, and renal clearance (CLR) at a given dose showed no significant difference between rats with and without bile fistulas. The plasma unbound fraction (fu) (0.006—0.026) increased with increasing plasma GLZ concentration over the observed range (2—900 μg/ml). No significant change in Vdss for unbound GLZ was observed between the doses, indicating that the distribution of GLZ into tissues is not changed by an increase in dose. On the other hand, a dose dependency in CLR for unbound GLZ was observed and confirmed to be attributed to dose dependency in CLR for unbound GLZ since there was no significant difference in CLR or metabolic clearance for unbound GLZ between the doses. The biliary excretion rates (Vb) at steady-state plasma unmetabolized levels followed the Michaelis-Menten type equation with a maximum Vb of 98.77 mg/min and a Michaelis constant of 1.83 μg/ml. It was suggested that the saturable Vb may result in the dose dependence of CLR.

Thus, the pharmacokinetics of GLZ in rats is dose-dependent.

Keywords: glycyrrhizin; dose dependency; rat; biliary clearance; saturable biliary excretion rate; nonlinear pharmacokinetics

Introduction

Glycyrrhizin (GLZ) has frequently been used in the treatment of chronic hepatitis,1 allergic disorders,2—4 inflammation,5,5 and gastric ulcers.6 Recently GLZ has been reported to have produced some improvement in immuno function7 and an objective clinical improvement in patients with human immunodeficiency virus infection.8 However, GLZ produces the adverse effect of aldosteronism when given in massive doses.9—12 It is desirable, therefore, to elucidate the influence of dose on the pharmacokinetics of GLZ in order to use it safely in clinical therapeutics. Previously we reported the existence of enterohepatic cycling of GLZ following predominantly biliary excretion (ca. 80%) after a 100 mg/kg i.v. dose in rats,13 but we did not characterize the pharmacokinetics at any dose.

In this study, we examined whether GLZ shows dose-dependent pharmacokinetics in rats by measuring the plasma disappearance after an i.v. administration of 5, 10, 20, or 50 mg/kg and the biliary excretion.

Experimental

Chemicals Monoammonium glycyrrhizinate (GLZ-NH4) was kindly supplied by Minophagen Pharmaceutical Co. (Tokyo, Japan). All other reagents were commercial products of analytical grade.

Animals Male Wistar rats (weighing 240—260 g) that had been starved for 20 to 24 h prior to the experiments were used throughout. Rats were lightly anesthetized with ether for all surgical procedures. The right femoral vein and left femoral artery were cannulated with PE-50 polyethylene tubing for i.v. injection and infusion of the drug and for blood sampling, respectively. A bile fistula cannula (PE-10 polyethylene tubing) and a urinary bladder cannula (PE-60 polyethylene tubing) were used to collect samples of bile and urine, respectively. The cannulated rats were kept in restraining cages with free access to water under normal housing conditions prior to the experiments. The rats were allowed to recover from anesthesia prior to the drug administration (approximately 1 h). The body temperature was kept at 37°C throughout the experiments by using a heat lamp.

Plasma Disposition GLZ-NH4 dissolves in a 5% glucose solution (5, 10, 20, or 50 mg/kg as GLZ) (ca. 1.0 ml/kg) each was given to rats with and without biliary fistulization, followed by 0.5 ml of 5% glucose solution. After dosing, blood samples (0.3 ml each) were collected in heparinized polyethylene centrifuge tubes at 1, 5, 10, 30, 60, and 120 min. Further samples were taken at 3 h after the 10 mg/kg dose, at 3 and 5 h after 20 mg/kg, and at 3, 5, 8 and 12 h after 50 mg/kg. Rats were given fresh blood (1.5 ml) obtained from other rats, through the left femoral artery cannula immediately after sampling at 60 min. Plasma was harvested immediately and frozen at −20°C until analysis.

Biliary and Urinary Excretion In bile fistula rats, bile samples were obtained at 0—0.5, 0.5—1, 1—2, 2—4, 4—8, 8—12, 12—24, and 24—48 h after i.v. administration of GLZ (5, 10, 20, or 50 mg/kg), and urine samples were obtained at 0—12, 12—24, and 24—48 h. Urine samples were similarly collected from rats without bile fistulas after an i.v. administration of GLZ.

Biliary Excretion Rate (Vb) at Steady-State Plasma Level (Cb) After a loading dose of 1, 1.1, 2.2, 4.4, 14.0, or 18.0 mg/kg GLZ, the drug was infused through the cannula at the rate of 3.7, 7.4, 14.9, 30.0, or 35.0 mg/min, respectively, with a constant-rate infusion pump (model KN-201, Natsume Seisakusho Co., Tokyo, Japan). The Cb (ca. 10—500 μg/ml) was obtained within 45 min after the initiation of infusion in each case. A point 60 min after the initiation of infusion was taken as zero time, and bile was collected over 15 min intervals for 60 min through the cannula. The volume of each bile sample was measured and samples were combined after GLZ determination. All the samples were stored at −20°C until required.

Determination Method Samples of plasma and bile (20—100 μl) were used for GLZ determination by the method described previously, i.e., by high-performance liquid chromatography (HPLC)14 after extraction with MeOH.15

Data Analysis The area under the plasma concentration curve (AUC) and the mean residence time (MRT) were calculated by trapezoidal integration with extrapolation to infinite time.16 The steady-state distribution volume (Vdss) and total body clearance (CLint) were calculated from dose MRT/AUC and dose/AUC, respectively. The biliary (CLb) and renal (CLR) clearances were calculated from the total biliary and urinary excreted amounts divided by AUC, respectively.

Metabolic clearance (CLR) in the rats with a bile fistula was estimated from CLRint — (CLb + CLR). The Vb at Cb was estimated from Bmax × Bmean/60 min, where Bmax and Bmean are the total volume of four bile samples collected at Cb and the mean GLZ concentration in those samples, respectively. The AUC data were analyzed according to Eq. 1, and the maximum Vb (Vb,max) and Michaelis constant (Km) were calculated by a nonlinear least-squares method17 using a digital computer (NEC PC-9801 RA).

$$V_{b} = \frac{V_{b,\text{max}} \cdot C_{b,\text{t}}}{K_{m} + C_{b,\text{t}}}$$

Where Cb, t is the steady-state plasma unbound concentration. Unbound plasma concentration (Cb) of GLZ was calculated from the equation defined

© 1992 Pharmaceutical Society of Japan


NII-Electronic Library Service
in the previous report as follows:

\[
C_{tot} = C_t + \frac{n_1(p)K_1C_1}{1 + K_1C_1} + \frac{n_2(p)K_2C_2}{1 + K_2C_2}
\]  

where \( C_{tot} \) is the total plasma concentration of GLZ, and \( K_1 \) and \( K_2 \) are the association constants corresponding to \( n_1(p) \) and \( n_2(p) \), which are the primary and secondary binding capacities, respectively. By using the values given in the previous paper for \( n_1(p) \) (1.35 mm), \( n_2(p) \) (6.83 mm), \( K_1 \) (124.2 mm⁻¹), and \( K_2 \) (0.095 mm⁻¹), and \( C_{tot} \) \( C_1 \) was calculated from a cubic equation by using the Hitchcock-Baird program on a digital computer. Plasma unbound fraction (\( f_p \)) was estimated from \( C_1/C_{tot} \). All means are presented with their standard error (mean ± S.E.). Student's t-test was utilized to determine the significance of differences between doses and between the rat groups with and without bile fistulas.

Results

Pharmacokinetic Aspects  The plasma disposition of GLZ after an i.v. administration of 5, 10, 20, or 50 mg/kg in rats with and without biliary fistulation is plotted in Fig. 1. The decline in mean plasma concentration was biphasic in all cases, but with a much slower terminal disposition at the two high doses than at the two low doses. Table I shows the pharmacokinetic parameters for the rats without bile fistulas. The \( AUC \) value increased proportionally to the administered dose at doses of 5 and 10 mg/kg, but the increases at 20 and 50 mg/kg were greater than the proportional increase of dose. The \( MRT \) and \( Vd_{tot} \) values at 20 and 50 mg/kg were significantly larger (\( p < 0.05 \)) than those at 5—10 and 5—20 mg/kg, respectively. The \( CL_{tot} \) values at 20 and at 50 mg/kg were significantly smaller (\( p < 0.05 \)) than those at 5—10 and 5—20 mg/kg, respectively, while no significant difference in the \( CL_{tot} \) values was observed between the doses. As shown in Table II, in the rats with bile fistulas, the \( AUC \) also showed linear and nonlinear increases in dose ranges of 5 to 10 mg/kg and 20 to 50 mg/kg, respectively. Statistically significant differences in the \( MRT \), \( Vd_{tot} \), and \( CL_{tot} \) values between the doses were similar to those in the rats without bile fistulas. The \( CL_{tot} \) values at 20 and 50 mg/kg were significantly smaller (\( p < 0.05 \)) than those at 5—10 and 5—20 mg/kg, respectively, while no significant difference in the \( CL_{tot} \) and \( CL_{tot} \) values was obtained between the doses. Neither \( AUC \), \( MRT \), \( Vd_{tot} \), \( CL_{tot} \), or \( CL_{tot} \) at a given dose showed any significant difference between the two groups. The \( f_p \) (0.006—0.026)

![Figure 1: Plasma Disposition Curves of GLZ after i.v. Administration of 5, 10, 20, or 50 mg/kg to Rats](image)

Each point represents the mean ± S.E. of four to six rats without (A) and with (B) bile fistulas. ○, 5 mg/kg; ●, 10 mg/kg; ▲, 20 mg/kg; □, 50 mg/kg.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>5 mg/kg</th>
<th>10 mg/kg</th>
<th>20 mg/kg</th>
<th>50 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>( AUC ) (min·mg/ml)</td>
<td>2.62 ± 0.10</td>
<td>5.04 ± 0.12</td>
<td>13.0 ± 1.2</td>
<td>41.9 ± 1.3</td>
</tr>
<tr>
<td>( MRT ) (min)</td>
<td>30.7 ± 1.9</td>
<td>30.2 ± 1.4</td>
<td>51.7 ± 2.8 (^{1})</td>
<td>96.1 ± 12.9 (^{a})</td>
</tr>
<tr>
<td>( Vd_{tot} ) (ml/kg)</td>
<td>58.2 ± 2.3</td>
<td>59.8 ± 3.2</td>
<td>86.4 ± 6.1 (^{1})</td>
<td>115.0 ± 16.2 (^{a})</td>
</tr>
<tr>
<td>( CL_{tot} ) (ml/min/kg)</td>
<td>1.91 ± 0.06</td>
<td>1.98 ± 0.09</td>
<td>1.54 ± 0.08 (^{1})</td>
<td>1.20 ± 0.04 (^{a})</td>
</tr>
<tr>
<td>( CL_{tot} ) (ml/min/kg)</td>
<td>0.02 ± 0.01</td>
<td>0.04 ± 0.02</td>
<td>0.04 ± 0.01</td>
<td>0.06 ± 0.02</td>
</tr>
</tbody>
</table>

Results are given as the mean ± S.E. of four to six rats. \(^{a}\) The area under the plasma concentration curve. \(^{b}\) The mean residence time. \(^{c}\) The total body and renal clearances, respectively. \(^{1}\) Significant difference (\( p < 0.05 \)) from 5 and 10 mg/kg. \(^{a}\) Significant difference (\( p < 0.05 \)) from 5, 10, and 20 mg/kg. For the calculations, see the text.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>5 mg/kg</th>
<th>10 mg/kg</th>
<th>20 mg/kg</th>
<th>50 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>( AUC ) (min·mg/ml)</td>
<td>2.58 ± 0.23</td>
<td>5.10 ± 0.37</td>
<td>13.5 ± 1.3</td>
<td>43.1 ± 3.4</td>
</tr>
<tr>
<td>( MRT ) (min)</td>
<td>30.1 ± 2.6</td>
<td>31.4 ± 2.3</td>
<td>52.4 ± 5.0</td>
<td>97.2 ± 7.2 (^{a})</td>
</tr>
<tr>
<td>( Vd_{tot} ) (ml/kg)</td>
<td>58.3 ± 5.2</td>
<td>60.5 ± 4.5</td>
<td>77.6 ± 6.5 (^{a})</td>
<td>112.8 ± 10.7 (^{a})</td>
</tr>
<tr>
<td>( CL_{tot} ) (ml/min/kg)</td>
<td>1.94 ± 0.17</td>
<td>1.96 ± 0.14</td>
<td>1.48 ± 0.14 (^{1})</td>
<td>1.16 ± 0.08 (^{a})</td>
</tr>
<tr>
<td>( CL_{tot} ) (ml/min/kg)</td>
<td>1.85 ± 0.14</td>
<td>1.82 ± 0.12</td>
<td>1.33 ± 0.11 (^{1})</td>
<td>1.00 ± 0.07 (^{a})</td>
</tr>
<tr>
<td>( CL_{tot} ) (ml/min/kg)</td>
<td>0.02 ± 0.01</td>
<td>0.03 ± 0.01</td>
<td>0.03 ± 0.01</td>
<td>0.05 ± 0.02</td>
</tr>
<tr>
<td>( CL_{tot} ) (ml/min/kg)</td>
<td>0.07 ± 0.03</td>
<td>0.11 ± 0.02</td>
<td>0.11 ± 0.02</td>
<td>0.10 ± 0.03</td>
</tr>
</tbody>
</table>

Results are given as the mean ± S.E. of four to six rats. \(^{a}\) and \(^{b}\) The biliary and metabolic clearances, respectively. \(^{1}\) Significant difference (\( p < 0.05 \)) from 5 and 10 mg/kg. \(^{a}\) Significant difference (\( p < 0.05 \)) from 5, 10, and 20 mg/kg. For other keys and the calculations, see Table I and the text, respectively.
increased gradually with increasing plasma concentration over the observed range (2—900 μg/ml) (Fig. 2), suggesting that plasma protein binding may be involved in changes in pharmacokinetic parameters.

**Biliary Excretion**  Figure 3 shows the cumulative biliary excretion profile of GLZ following an i.v. dose of 5, 10, 20, or 50 mg/kg. The excretion was no longer detectable at 48 h after any dose. Biliary excretion tended to slow with increasing dose until 8 h, but the total excretion showed no significant difference between the doses (95.7 ± 2.9, 92.2 ± 2.2, 90.2 ± 4.5, and 85.9 ± 6.0% of the dose at 5, 10, 20, and 50 mg/kg, respectively). As can be seen in Fig. 4, the $V_B$ seemed to be saturable with increasing $C_{ss,f}$. Therefore, the $V_B$ data were analyzed according to the Michaelis-Menten type equation (Eq. 1), and $V_{B,max}$ (98.77 μg/min) and $K_m$ (1.83 μg/ml) were estimated by a nonlinear least-squares method$^{17}$ as the analysis by Eq. 1 with a term of linear biliary excretion failed to give converged parameters. The simulated line follows well the experimental points. This suggests that the saturable $V_B$ might account for the dose dependence of $CL_B$. Figure 5 shows the ratio ($R_B$) of $B_{cor}$-to-$C_{ss,f}$. The $R_B$ was approximately 2100—7400 times higher than the range of $C_{ss,f}$ and showed a gradual decrease with increasing $C_{ss,f}$.

**Discussion**  Previously we confirmed the existence of enterohepatic cycling of GLZ following i.v. administration of 100 mg/kg to rats$^{13}$ and the absorption of GLZ from rat intestinal tract.$^{13,19}$ In the present study, GLZ was also found to be excreted predominantly in bile. Nevertheless, although enterohepatic cycling may have occurred, it showed no apparent influence on the $AUC$ value at any dose, as described already. This may be because the total biliary excretion amount at 5—50 mg/kg is less than that at 100 mg/kg (the excretion ratio is almost constant at ca. 80—96% at these doses) and the rat intestinal absorption clearance ($CL_{abs}$) value is small (0.310 ± 0.021 ml/min).$^{19}$ For comparison, the $CL_{abs}$ of salicylic acid in rats is 1.10 ml/min ($CL_{abs}$, 13.6 μl/min/cm$^{2}$$^{20}$) × total small intestinal length 80.8 cm$^{21}$), determined by the same method as in the case of GLZ. Also, GLZ might almost be metabolized by rat intestinal bacteria, as the drug is metabolized by human intestinal bacteria.$^{22}$ Since the participation of
plasma protein binding in changes in pharmacokinetic parameters was suggested, the nonlinearity in $V_{dss}$, $CL_{tot}$, and $CL_B$ owing to the increase of $f_p$ was examined by calculating the steady-state distribution volume ($V_{dss}$) and total body ($CL_{tot}$) and biliary ($CL_B$) clearances for $C_I$ in rats with bile fistulas, as well as renal ($CL_R$) and metabolic ($CL_M$) clearances for $C_I$. The calculated values are shown in Fig. 6, together with those at 100 mg/kg GLZ, which were estimated by using $f_p$ (0.006—0.197) at the observed range of plasma concentrations (2—1600 μg/ml) in rats with bile fistulas.13 The $V_{dss}$ values were almost constant at various dose levels. It was found that the distribution of GLZ into tissues is not changed by the increase in dose. Whereas, the $CL_{tot}$ and $CL_M$ decreased gradually with increasing dose. The values of $CL_M$ were approximately 5—50 times larger than those of $CL_R$ and $CL_M$, which showed no significant difference between any doses. Thus, the dose dependency in $CL_{tot}$ was confirmed to be ascribed to that in $CL_B$. In the case of 100 mg/kg dose, the mean $CL_B$ value (0.72 ml/min/kg) was smaller than that at 50 mg/kg and the mean $CL_R$ (0.04 ml/min/kg) and $CL_M$ (0.18 ml/min/kg) values were similar to those at 5—50 mg/kg (Table II), respectively. This further supports the idea that the dose dependency in $CL_{tot}$ is due to that in $CL_B$. The dose dependence of $CL_B$ might be attributed to the saturable $V_{b}$ (Fig. 4), as described already. Further, it was suggested that an active transport process may be involved in biliary excretion, as $R_B$ was 2100—7400 times higher than the range of $C_{Mss}$ (Fig. 5).

It has been reported that the total biliary excretion of GLZ was approximately 80% of the i.v. dose (80 mg/man) in a cholangiocarcinomatous patient with liver failure, and the $AUC$ value increased proportionally with i.v. dose (40, 80, and 120 mg/man) in three normal humans.23 From the data in our previous report, human serum clearances of 0.25—0.36 ml/min/kg in three normal subjects19 and 0.16—0.45 ml/min/kg in five patients with chronic hepatitis after GLZ i.v. dosing (80 and 200 mg/man, respectively) are calculated on the assumption of 70 kg body weight. These values are approximately 4—12 times smaller than the mean $CL_{tot}$ value at 5 mg/kg in rats (Table I). This might suggest dose-dependent $CL_{tot}$ at a massive dose (e.g., 200 mg/man) and upon consecutive administrations of GLZ to humans. But dose-dependent $V_{dss}$ may not be observed, because GLZ showed uniformly high binding of 99.6% over the observed range of human serum levels (2—60 μg/ml) after i.v. administration (80 and 200 mg/man).25,26

In summary, the pharmacokinetics of GLZ in rats is dose-dependent. Such pharmacokinetic properties are likely to be an important factor in the establishment of suitable dosage regimens.

References

2) S. Sotomatsu, Y. Takahashi, J. Hiroi, A. Namikawa, and N. Okano, Hifuj To Hinyo, 21, 138 (1959).
11) A. Ullman, J. Menard, and P. Corcoran, Endocrinology, 97, 46 (1975).